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Type 2 diabetes is associated with significant cardiovascular morbidity and mortality. Although low-density lipopro-
tein cholesterol levels may be normal in patients with type 2 diabetes, insulin resistance drives a number of
changes in lipid metabolism and lipoprotein composition that render low-density lipoprotein cholesterol and other
lipoproteins more pathogenic than species found in patients without type 2 diabetes. Dyslipidemia, which affects
almost 50% of patients with type 2 diabetes, is a cardiovascular risk factor characterized by elevated triglyceride
levels, low high-density lipoprotein cholesterol levels, and a preponderance of small, dense, low-density lipoprotein
particles. Early, aggressive pharmacological management is advocated to reduce low-density lipoprotein cholesterol
levels, regardless of baseline levels. A number of lipid-lowering agents, including statins, fibrates, niacin, and bile
acid sequestrants, are available to target normalization of the entire lipid profile. Despite use of combination and
high-dose lipid-lowering agents, many patients with type 2 diabetes do not achieve lipid targets. This review out-
lines the characteristics and prevalence of dyslipidemia in patients with type 2 diabetes and discusses strategies
that may reduce the risk of cardiovascular disease in this population.
Introduction
Type 2 diabetes affects approximately 24 million indivi-
duals in the United States [1] and is associated with sig-
nificant morbidity and mortality due to cardiovascular
complications [2]. The incidence of cardiovascular dis-
ease (CVD) is more common in patients with type 2
diabetes than in the general population [3]. Dyslipide-
mia, an established risk factor for CVD, is strikingly
common in patients with type 2 diabetes, affecting
almost 50% of this population [4]. In addition to hyper-
glycemia and hypertension, dyslipidemia is a modifiable
CVD risk factor that remains largely uncontrolled in
patients with type 2 diabetes [4].
Hyperglycemia increases the risk of microvascular
complications [5], while dyslipidemia is a major risk fac-
tor for macrovascular complications in patients with
type 2 diabetes [6,7]. Elevated low-density lipoprotein
cholesterol (LDL-C) is a major risk factor for CVD [6].
As such, management of LDL-C is the primary goal of
therapy for diabetic dyslipidemia [8-10]. Furthermore,
type 2 diabetes increases the risk of CVD mortality
independent of LDL-C levels, adding to the greater
overall cardiovascular risk in this population [11].
Therefore, aggressive lipid treatment goals have been
recommended for patients with type 2 diabetes
(Table 1) [8-10,12]. As the prevalence of type 2 diabetes
increases in the United States, prevention of CVD is
becoming an increasingly urgent public health concern,
requiring aggressive management of the entire lipid pro-
file [8]. This review outlines the characteristics and pre-
valence of dyslipidemia in patients with type 2 diabetes
and discusses strategies that may reduce the risk of
CVD in this population.
Characteristics and mechanisms of lipoprotein
abnormalities in type 2 diabetes
The hallmarks of type 2 diabetes are hyperglycemia, insu-
lin resistance, and insulin deficiency, and it is increasingly
recognized that insulin resistance contributes to the char-
acteristic dyslipidemia associated with type 2 diabetes [13].
Disturbance of lipid metabolism appears to be an early
event in the development of type 2 diabetes, potentially
preceding the disease by several years [14]. In addition, the
different components of diabetic dyslipidemia (plasma
lipid and lipoprotein abnormalities) are believed to be
metabolically linked [13,15]. The dyslipidemia associated
with insulin resistance (also referred to as atherogenic
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glyceride (TG) levels carried in very-low-density lipopro-
tein (VLDL) particles, reduced high-density lipoprotein
cholesterol (HDL-C) levels carried in small HDL particles,
and LDL-C levels that do not differ substantially from
those of individuals without type 2 diabetes (Figure 1)
[13,15-17]. In addition, TG-rich lipoproteins (after eating),
remnant lipoproteins, apolipoprotein B 100 (ApoB), and
small, dense HDL particles have also been shown to be
increased in patients with type 2 diabetes [18]. In patients
with type 2 diabetes, LDL particles are small and dense,
carrying less cholesterol per particle; therefore, at any
given LDL-C concentration, there are more LDL particles
present in an individual with type 2 diabetes relative to an
individual without the disease, which may make the LDL-
C level a misleading measure of risk in patients with type
2 diabetes [8].
The association between hyperglycemia and microvas-
cular complications in type 2d i a b e t e si su n e q u i v o c a l
[5,19]. However, dyslipidemia may correlate more
directly with cardiovascular complications [2], and
mechanistic evidence is emerging regarding the greater
lipocentric versus glucocentric nature of CVD risk in
patients with type 2 diabetes [7,18]. Insulin resistance is
central to the pathogenesis of type 2 diabetes and con-
tributes to dyslipidemia [17]. Insulin resistance is asso-
ciated with increased levels of serum insulin and
depletion of b-cells and results in impaired regulation of
circulating lipoprotein and glucose levels [7,13]. Data
suggest impairment in the ability of insulin to suppress
hepatic production of large TG-rich VLDL (VLDL-TGs)
in patients with type 2 diabetes results in a subsequent
elevation in plasma TG levels (Figure 1) [13-15].
Impaired insulin action at the level of the adipocyte is
believed to result in defective suppression of intracellu-
lar hydrolysis of TGs with the release of nonesterified
(free) fatty acids (NEFAs) into the circulation [17]. The
increased influx of NEFAs to the liver promotes TG
synthesis and the assembly and secretion of large VLDL;
this results in elevated plasma VLDL levels (hypertrigly-
ceridemia) and postprandial hyperlipidemia that is com-
pounded by impaired lipoprotein lipase activity - the
latter regarded as independently associated with coron-
ary artery disease. Hypertriglyceridemia can trigger
thrombogenic alterations in the coagulation system. In
addition, elevated VLDL-TGs reduce levels of cardiopro-
tective HDL-C as TGs are transferred when these parti-
cles collide. The reduction in HDL-C levels is
accompanied by a reduction in antioxidant and anti-
atherogenic activities. Of note, VLDL-enhanced TG
enrichment of HDL-C and LDL-C by exchange of TG
Table 1 Low-density Lipoprotein Cholesterol (LDL-C) and Non-HDL-C Goals for Patients in Different CVD Risk
Categories from the Adult Treatment Panel III of the National Cholesterol Education Program [12,30]
Risk Category Goals (mg/dL)
Primary target: LDL-C Secondary target: Non-HDL-C
‡
CVD + T2DM (CVD risk equivalent)* < 70 < 100
CVD or T2DM
† < 100 < 130
≥ 2 risk factors (not CVD risk equivalents) < 130 < 160
0-1 risk factor (not a CVD risk equivalent) < 160 < 190
CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; T2DM, type 2 diabetes mellitus; non-HDL-C = LDL-C + very-low-density lipoprotein
cholesterol (VLDL-C) or total cholesterol - HDL-C.
*In addition to reduction of LDL-C to a goal of < 70 mg/dL as an option in very high-risk patients with overt CVD (level of evidence B), additional American Diabetes
Association (ADA) recommendations are the reduction of LDL-C by 30%-40% in all patients with diabetes and overt CVD, regardless of baseline LDL-C levels (level of
evidence A); lower triglycerides to < 150 mg/dL and raise HDL-C to > 40 mg/dL, with the option of > 50 mg/dL in women (level of evidence C) [10].
†In addition to the reduction of LDL-C to < 100 mg/dL as the primary therapeutic goal (level of evidence A), the ADA recommends that LDL-C be reduced by
30%-40% in all patients with diabetes > 40 years of age without overt CVD, regardless of baseline LDL-C levels (level of evidence C) [10].
‡Non-HDL-C is a secondary target of therapy in patients with high serum triglycerides (≥ 200 mg/dL) [30].
Figure 1 Atherogenic dyslipidemia and changes in lipoprotein
metabolism associated with type 2 diabetes mellitus [51].
Insulin resistance is associated with enhanced production of very-
low-density lipoprotein (VLDL); a reduction in the catabolic rate of
intermediate-density lipoprotein (IDL) and small, dense low-density
lipoprotein (sdLDL); increased production of high-density lipoprotein
(HDL) outweighed by increased catabolism. Adapted with
permission from Adiels et al, Overproduction of very low-density
lipoproteins is the hallmark of the dyslipidemia in the metabolic
syndrome. Arterioscler Thromb Vasc Biol 28(7): 1225-1236 (2008) [14].
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hydrolysis of the TG portion, resulting in small, rela-
tively cholesterol-poor HDL (which are subsequently
catabolized and cleared from the circulation) and LDL
particles [18]. When LDL particles become small and
dense, they are more prone to oxidation and more read-
ily adhere to and subsequently invade the arterial wall,
contributing to atherosclerosis; small, dense LDL parti-
cles are therefore regarded as more atherogenic than
their larger, more buoyant precursor [17].
Cholesterol ester transfer protein (CETP) is also
known to play a pathological role in diabetic dyslipide-
mia, particularly in the reduction of HDL-C levels due
to increased catabolism [20]. This finding has lead to
the speculation that CETP inhibition may increase
HDL-C levels, and several CETP inhibitors are in devel-
opment. Failure of the first of these, torcetrapib, due to
increased incidence of adverse cardiovascular events, has
led to concerns about the utility of CETP as a therapeu-
t i ct a r g e t .H o w e v e r ,s i n c ei n c r e a s e si nb l o o dp r e s s u r e
(BP) and plasma aldosterone levels were reported with
torcetrapib, it is possible that off-target effects were
responsible for the adverse outcomes rather than CETP
inhibition itself [21]. BP and plasma aldosterone
increases have not been reported with anacetrapib - the
second CETP inhibitor in development [22,23].
Activation of the renin-angiotensin-aldosterone system
(RAAS) can interfere with insulin signaling as well, pro-
moting and exacerbating insulin resistance in patients
with type 2 diabetes. RAAS activation increases oxida-
tive stress, decreases nitric oxide production, and acti-
vates protein kinase signaling pathways, leading to
excess generation of angiotensin II, endothelial damage,
and vascular complications in patients with type 2 dia-
betes, resulting in an increased risk of CVD [24,25].
Inhibition of RAAS with an angiotensin-converting
enzyme inhibitor reduces the risk of death from cardio-
vascular causes in patients with type 2 diabetes [24,26].
The prevalence of dyslipidemia in association
with type 2 diabetes
Data from the United States National Health and Nutri-
tional Examination Survey (NHANES) 1999-2000 show
that < 50% of 498 adults with type 2 diabetes had total
cholesterol (TC) levels < 200 mg/dL despite > 50% of
these patients receiving medication for dyslipidemia
[4,27]. Furthermore, there was little difference in the pro-
portion of patients with LDL-C < 100 mg/dL in the
population with type 2 diabetes versus the nondiabetic
population (25.3% vs 24.3%, respectively). However, sig-
nificantly fewer patients with type 2 diabetes had HDL-C
and TG at optimal levels compared with patients without
type 2 diabetes (Figure 2) [27]. Consistent with the data
from NHANES 1999-2000, data from the United
Kingdom Prospective Diabetes Study (UKPDS) in 3713
newly diagnosed patients with type 2 diabetes reported
that HDL-C levels were lower (by 9% [men] and 23%
[women]) while TG levels were 50% higher in patients
with type 2 diabetes than in nondiabetic patients; LDL-C
v a l u e sw e r es i m i l a r( f o rm a l e sb u th i g h e ri nf e m a l e s )
between those with and without type 2 diabetes [2]. As
the pattern of elevated lipids was more pronounced in
females, it was suggested to contribute to the greater car-
diovascular risk in females compared with males [2].
Data from NHANES 1999-2000 showed that among
patients with type 2 diabetes receiving treatment for dys-
lipidemia, control of LDL-C was only achieved in 29.7%
of patients, and optimal levels of LDL-C, HDL-C, and
TG were only achieved in 3.4% of patients; these data
were comparable to those in patients with type 2 diabetes
who were untreated for dyslipidemia (Figure 3) [27].
Cardiovascular risk associated with dyslipidemia
and treatment goals for patients with type 2
diabetes
In SHIELD (Study to Help Improve Early evaluation and
management of risk factors Leading to Diabetes), a com-
munity-based population survey conducted in the Uni-
ted States, a multivariate analysis of self-reported data
from 22,001 patients showed that dyslipidemia was inde-
pendently associated with a higher likelihood of type 2
diabetes diagnosis (odds ratio, 3.95; P< 0.0001) [28].
Moreover, it is increasingly recognized that the risk of
cardiovascular events is increased in patients with type 2
diabetes and that dyslipidemia is a contributing factor
with often fatal outcomes [9]. Optimal management
strategies have not been fully elucidated. Although the
focus has largely been on lowering LDL-C levels, the
benefits associated with targeting other lipids and lipo-
proteins are emerging.
EUROASPIRE (EUROpean Action on Secondary Pre-
vention through Intervention to Reduce Events) was a
large survey performed to assess current clinical practice
in relation to reporting and management of risk factors
in the secondary prevention of coronary heart disease
(CHD). Data from EUROASPIRE showed a high preva-
lence of modifiable risk factors, including smoking,
weight, hypertension, dyslipidemia, type 2 diabetes, and
lack of screening in first-degree blood relatives, among
patients with CHD [29].
LDL-C
The relationship between LDL-C and CVD risk is contin-
uous over a broad range of LDL-C levels in patients with
and without type 2 diabetes, and the National Cholesterol
Education Program Adult Treatment Panel III (NCEP
ATP III) recommends target lipid levels for patients with
type 2 diabetes and dyslipidemia (Table 2) [30].
Vijayaraghavan Lipids in Health and Disease 2010, 9:144
http://www.lipidworld.com/content/9/1/144
Page 3 of 12Elevated LDL-C levels are more pathogenic in those
with type 2 diabetes due to the presence of small, dense
LDL particles and other potentially atherogenic lipopro-
teins, such as VLDL and intermediate-density lipopro-
tein (IDL) [9,14,17,31], and data have demonstrated that
lowering LDL-C levels reduces the risk for major CVD
events in patients with type 2 diabetes [8]. Data from
CARDS (Collaborative Atorvastatin Diabetes Study)
demonstrated a clinical benefit (37% reduction in the
first incidence of a major cardiovascular event; P =
0.001) with atorvastatin in patients (n = 2838) with type
2 diabetes whose lipid profile was not highly elevated,
highlighting the importance of lipid modification for pri-
mary prevention of CVD in patients with type 2 diabetes
[32]. Similarly, in the Heart Protection Study (HPS) in
patients (n = 2912) with type 2 diabetes and no known
coronary or other occlusive disease, simvastatin was
associated with a 33% reduction (P = 0.0003) in coron-
ary event rate over 5 years of treatment [33]. Impor-
tantly, the CVD benefits observed in CARDS and HPS
were associated with a reduction in LDL-C, independent
of baseline LDL-C level [8].
Further evidence of cardiovascular risk reduction with
intensive control of LDL-C in patients with type 2 dia-
betes comes from ASCOT-LLA (Anglo-Scandinavian
Cardiac Outcomes Trial-Lipid-Lowering Arm) [34]. In
the cohort of 2532 patients with type 2 diabetes with
well-controlled (average or below) BP and cholesterol
levels, atorvastatin was associated with a reduction of
23% (P = 0.04) in total major CVD events or procedures
compared with placebo; corresponding reductions in TC
and LDL-C levels were 17% and 27%, respectively [34].
In addition, the Treating to New Targets (TNT) study
demonstrated the benefits ofr e d u c i n gL D L - Ct ob e l o w
currently recommended levels in higher-risk patients. In
the 1501 patients with type 2 diabetes and CVD, inten-
sive statin therapy provided an additional 25% reduction
in major CVD events over 5 years (P =0 . 0 3 )[ 3 5 ] .I na
meta-analysis of data from 14 randomized trials in
18,686 patients with diabetes (17,220 patients with type
2 diabetes), statin therapy was associated with a signifi-
cant reduction in all-cause mortality (P =0 . 0 2 )p e r
mmol/L reduction in LDL-C, reflecting a significant
reduction in vascular mortality (P =0 . 0 0 8 ) .R e d u c t i o n s
Figure 2 Prevalence of target low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and
triglyceride (TG) levels for patients with and without type 2 diabetes mellitus (T2DM): National Health and Nutrition Examination
Survey 1999-2000.* P< 0.001 vs patients with T2DM. Reprinted from Diabetes Res Clin Pract, 70(3), Jacobs MJ, et al, 263-269, Copyright 2005,
with permission from Elsevier [27].
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and other baseline characteristics and were similar to
those seen in patients without diabetes [36]. These stu-
dies support recommendations from the American Dia-
betes Association (ADA) of LDL-C targets for patients
with type 2 diabetes of < 100 mg/dL in low-risk patients
and < 70 mg/dL in high-risk patients (Table 1), as well
as reducing LDL-C by 30% to 40% in all patients aged >
40 years, and in all patients with overt CVD, regardless
of baseline LDL-C status; these recommendations are
also supported by the American Heart Association [8].
Although there appears to be almost overwhelming evi-
dence for links between dyslipidemia and cardiovascular
risk and between normalization of lipid levels and reduced
cardiovascular risk, the data are not completely consistent.
Positive data should be viewed in context with more nega-
tive data such as those seen in ASPEN (Atorvastatin Study
for Prevention of coronary heart disease Endpoints in
Non-insulin-dependent diabetes mellitus) [37]. ASPEN
was a 4-year double-blind, randomized trial to assess the
effect of atorvastatin on CVD prevention in 2410 patients
with type 2 diabetes and normal LDL-C levels. In this
study, mean LDL-C was significantly lowered with atorvas-
tatin versus placebo (P < 0.0001); however, the composite
primary endpoint (cardiovascular death, nonfatal cardio-
vascular events) and secondary individual endpoints were
not significant [37]. Available data also suggest that
increasing HDL-C levels alone does not reduce cardiovas-
cular morbidity or mortality. In a meta-analysis of 108
randomized trials involving 299,310 patients at risk of car-
diovascular events, changes in HDL-C did not correlate
with cardiovascular outcomes or mortality, and the results
support LDL-C reduction as the primary goal for lipid-
modifying interventions [38].
TG, HDL-C, and Non-HDL-C
In the UKPDS, a multivariate analysis found that LDL-C
was the strongest independent predictor of CVD, fol-
lowed by HDL-C, while modestly elevated TG levels did
not predict CVD events [6], helping to justify current
national guidelines advocating LDL-C < 100 mg/dL as
the primary target for the management of dyslipidemia in
patients with type 2 diabetes (Table 1). Serum TG levels
are a surrogate for TG-rich lipoproteins (eg, VLDL-C),
Figure 3 Prevalence of target low-density lipoprotein cholesterol (LDL-C) and combined LDL-C, high-density lipoprotein cholesterol
(HDL-C) + triglyceride (TG) levels for patients with type 2 diabetes mellitus either treated or not treated for dyslipidemia: National
Health and Nutrition Examination Survey 1999-2000 [27].
Vijayaraghavan Lipids in Health and Disease 2010, 9:144
http://www.lipidworld.com/content/9/1/144
Page 5 of 12and non-HDL-C (LDL-C + VLDL-C or TC - HDL-C)
reflects the concentration of cholesterol within lipopro-
tein particles considered atherogenic [8,9]. Currently,
there is no evidence to demonstrate that lowering TG
levels is associated with a reduction in CVD events; as a
result, treatment to reduce TG levels in patients with
type 2 diabetes is of secondary importance (Table 1) [9].
While HDL-C level is a strong CVD risk predictor, clini-
cal evidence supporting the benefits of treatment aimed
at increasing HDL-C levels is modest; as a result, therapy
aimed at altering HDL-C in patients with type 2 diabetes
is also of secondary importance (Table 1) [9]. Although
not widely adopted, the ADA/American College of Cardi-
ology (ACC) support the NCEP ATP III recommendation
to use non-HDL-C as a secondary treatment target for
patients with TG levels > 200 mg/dL; in these patients,
the recommended non-HDL-C goal is 30 mg/dL higher
than the LDL-C goal (Table 1) [9].
ApoB
The small, dense LDL particles that accompany insulin
resistance provide a better assessment of the atherogenic
lipoprotein load than LDL-C level. Despite continued
recommendations to reduce LDL-C in all patients with
type 2 diabetes, the ADA/ACC has recognized limitations
(including cost, complexity, and lack of standardized
measurement techniques) in using LDL-C as a biomarker
to guide therapeutic decisions for patients at high meta-
bolic risk [9]. LDL particle concentration and apoB level
appear to be more closely associated with type 2 diabetes
and insulin resistance than LDL-C or non-HDL-C and
may therefore be better predictors of vascular events
[9,16,39,40]. Although it is possible to assess risk by mea-
suring LDL particle concentration using nuclear mag-
netic resonance (NMR) [41], this technique is not widely
available, relatively expensive, and of dubious accuracy
[9]. However, given that there is one particle of apoB in
each atherogenic lipoprotein particle (ie, LDL, IDL, and
VLDL), quantification of apoB should capture the total
burden of the most atherogenic particles [9,16,40], and
thus serve as a valuable marker of CVD risk [14].
Although the apoB assay has been standardized and does
not require a fasting sample, it is not yet widely available.
Nevertheless, secondary targets of therapy have been
recommended for apoB (for patients with uncomplicated
type 2 diabetes [< 90 mg/dL] and for patients with type 2
diabetes and other major risk factors [< 80 mg/dL]) [9].
ApoA-I
Data from epidemiological, observational, and interven-
tional studies also suggest an association between apoli-
poprotein A-I (apoA-I) and cardiovascular risk,
indicating that assessment of apoA-I in addition to apoB
may provide more accurate prediction of high cardiovas-
cular risk than conventional lipid parameters [42]. The
r a t i oo fa p o Bt oa p o A - Ih a sb e e ns h o w nt oc o r r e l a t e
with cardiovascular risk in children [43].
Improving dyslipidemia in patients with type 2
diabetes
Achievement of recommended lipid and lipoprotein tar-
gets usually requires pharmacological therapy in addi-
tion to lifestyle modifications (a low-fat/cholesterol diet
and physical activity). Although aggressive LDL-C con-
trol is recommended [10], evidence-based strategies are
needed to monitor the benefits and risks of pharma-
cotherapy aimed at surrogate markers [44] and to evalu-




Statin therapy is recommended as the initial pharmaco-
logical treatment for lowering LDL-C levels in patients
with type 2 diabetes who either have overt CVD or are
over 40 years old and have increased CVD risk [8,10];
however, even with adequate LDL-C lowering via statin
therapy, CVD risk remains high in many patients [8,9].
The beneficial effects of statin treatment are thought to
be mediated predominantly via lowering of LDL-C
Table 2 Classification of Lipid Levels from the National








100-129 Near or above optimal
130-159 Borderline high
160-189 High










≥ 500 Very high
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; TC, total cholesterol; TG, triglyceride; VLDL-C, very-low-density
lipoprotein cholesterol.
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may also play a role [9]. Statin treatment lowers non-
HDL-C more than apoB [40], and reaching the apoB
target usually requires more intensive therapy than that
required to achieve the non-HDL-C goal [46,47]. Com-
mon adverse events associated with statin use include
gastrointestinal upset and muscle aches, although dose-
related hepatoxicity and myotoxicity are the most clini-
cally significant adverse events [48]. Caution is recom-
mended in patients with severe renal impairment
(creatinine clearance < 30 mL/min). Studies have shown
that high-dose statin therapy is effective in achieving
LDL-C goals and associated with favorable effects on
lipoprotein subfractions in patients with type 2 diabetes,
which may translate into clinical benefits in terms of
anti-atherogenic potential and a subsequent reduction in
the risk of adverse cardiovascular outcomes [49,50].
Other lipid-lowering therapies
Niacin has been used to treat dyslipidemia in patients
with type 2 diabetes for over half a century [51].
Although niacin is the most effective agent for raising
HDL-C levels, high doses can worsen hyperglycemia
[10]. Additional adverse events associated with niacin
include flushing, itching, nausea, gastrointestinal upset,
hypotension, and tachycardia [48,51]. It has been sug-
gested that combination lipid-lowering therapy (eg, a
statin with a fibrate or niacin) may be necessary for
patients with diabetic dyslipidemia to achieve optimal
lipid levels; however, to date, such strategies have not
been adequately evaluated for their long-term effect on
CVD risk reduction or safety compared with lipid-low-
ering monotherapy [8-10]. Furthermore, the risk of
myopathy is thought to be greater when niacin is used
with a statin [51]. Niacin plus laropiprant - a prosta-
glandin D2 receptor antagonist and antiflushing agent -
has been used successfully to improve the lipid profile
with reduced niacin-associated flushing in patients
with type 2 diabetes [52]. In 2 large randomized stu-
dies in patients with primary hypercholesterolemia or
mixed dyslipidemia, the combination of niacin, laro-
piprant, and simvastatin significantly improved lipid
parameters with a similar tolerability profile versus nia-
cin/laropiprant alone, but with an increase in flushing
and other niacin-related adverse effects versus statin
alone [53,54].
Ezetimibe, a selective cholesterol absorption inhibitor, is
an effective lipid-lowering agent when used as monother-
apy and is useful in patients who are unable to tolerate sta-
tin therapy [51]. Ezetimibe can also be used in
combination with statin therapy for greater lipid-lowering
efficacy. Ezetimibe plus atorvastatin, for example, can pro-
vide LDL-C lowering equivalent to that achieved with
high-dose atorvastatin, but with better tolerability in some
patients, and may be a useful adjunctive therapy in
patients with type 2 diabetes who have demonstrated an
inadequate response to statin treatment [55].
Fibrates are useful for lowering TG and non-HDL-C
levels and increasing HDL-C, yet results from trials in
patients with type 2 diabetes have been controversial
[56]. In the FIELD (Fenofibrate Intervention and Event
Lowering in Diabetes) study in 9795 patients with type
2 diabetes, fenofibrate did not significantly affect the pri-
mary endpoint, coronary event rate, relative to placebo
(11% reduction) [57]. Nevertheless, FIELD did show that
combination therapy with a statin and fenofibrate is
safe. Recent results from the ACCORD (Action to Con-
trol Cardiovascular Risk in Diabetes) study provided
further insight into whether the combination of a statin
and a fibrate is safe and provides CVD benefits beyond
statin therapy alone. In this study in 5518 patients with
type 2 diabetes, there was no difference between combi-
nation therapy with a statin and fibrate compared with
statin therapy alone with respect to the primary out-
come (nonfatal myocardial infarction, nonfatal stroke, or
death from cardiovascular causes) [58]. Common
adverse events associated with fibrates include gastroin-
testinal disturbance, rash, headache, pancreatitis, myal-
gia, and myotoxicity (in rare instances - and possibly
more likely with gemfibrozil than with fenofibrate [59]).
Adjuvant fibrate therapy is not recommended in patients
with severe renal dysfunction, severe hepatic dysfunc-
tion, and preexisting gall bladder disease [48].
Glucose-lowering agents
In addition to their glucose-lowering properties, antidia-
betes agents that directly improve insulin resistance may
have effects on lipid levels, especially TG levels.
Although there may be no effect on HDL-C levels, these
agents may instead alter the ratio of lipoproteins in
HDL towards more anti-atherogenic HDL particles [48].
For example, metformin has been shown to reduce
LDL-C, TC, and TG levels and increase HDL-C levels
[60]. Similarly, pioglitazone has been shown to reduce
TG levels and increase HDL-C levels [61]. In contrast,
rosiglitazone has been sho w nt oi n c r e a s eL D L - C ,T C ,
and HDL-C levels, although this thiazolidinedione does
not affect TG levels [62]. A prospective study evaluating
the effects of 4 months of treatment with pioglitazone
or rosiglitazone in addition to statin therapy in 127
patients with type 2 diabetes showed that, despite simi-
lar findings regarding HbA1c and weight gain (no
changes from baseline in HbA1c and similar significant
weight gain in both groups at 4 months), pioglitazone,
but not rosiglitazone, was associated with significant
improvements in the lipid profile (P < 0.01) [63]. Inter-
estingly, both thiazolidinediones have been shown to
increase LDL particle size and decrease LDL oxidation –
conditions that impair atherosclerosis (pioglitazone
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been reported to improve HDL-C and TG parameters
when used as an add-on therapy in patients with type 2
diabetes who are already receiving metformin or sulfo-
nylurea therapy [65,66] and is more effective in improv-
ing lipid and apolipoprotein levels than rosiglitazone
plus sulfonylurea, in addition to ongoing statin therapy
[67]. Although the use of sulfonylurea monotherapy has
not been associated with significant changes in the lipid
profile, the addition of acarbose to sulfonylurea therapy
not only improves glycemic control, but also provides
improvements in lipid parameters, particularly TG
levels [68].
Dual lipid- and glucose-lowering agents
Accumulating evidence indicates that lipid and glucose
homeostasis are interrelated [69]. Both are affected by
bile acid-activated signaling pathways in the liver [70].
Indeed, bile acids have an established role in dietary
lipid absorption and cholesterol metabolism, and are
also signaling molecules that affect systemic endocrine
functions through multiple signaling pathways [71].
Agents that modulate bile acids may potentially affect
both cholesterol and glucose metabolism, and hence
dyslipidemia and hyperglycemia, in patients with type 2
diabetes [69,71,72].
Bile acid sequestrants are established agents for LDL-
C lowering. The bile acid sequestrant colesevelam low-
ers LDL-C when used as monotherapy (up to 18%)
[73] and can result in reductions of up to 48% when
used in combination with a statin in patients with
mild-to-moderate hypercholesterolemia [74]. In addi-
tion, colesevelam is the only lipid-lowering agent
approved to improve glucose levels in patients with
type 2 diabetes [75]. A pilot study, GLOWS (Glucose-
Lowering effect of WelChol Study), showed that cole-
sevelam significantly reduced LDL-C levels (11.7%) and
HbA1c (0.5%) compared with placebo when added to
existing metformin- and/or sulfonylurea-based therapy
in patients with type 2 diabetes [76]. In subsequent
trials, the addition of colesevelam to stable metformin-
, sulfonylurea-, or insulin-based therapy resulted in
additional reductions in LDL-C (12.8% to 16.7%) and
HbA1c (0.50% to 0.54%) (P< 0.001 vs placebo for all)
[77-79]. Consistent with a significant reduction in
apoB (11.8%) in GLOWS [76], improvements in
atherogenic lipoprotein subclasses measured by NMR
were also reported with colesevelam. The most signifi-
cant effect with colesevelam was seen on LDL particles
(15.5% reduction vs placebo; P = 0.006), primarily due
to an improvement in the number of small LDL parti-
cles (P = 0.054 vs placebo) [80]. Notably, the reduction
in LDL particles was the only lipid parameter corre-
lated with improvement in HbA1c [80].
The use of bile acid sequestrants in patients with type
2 diabetes has been a concern due to an association
with increased fasting TG levels. There was a nonsignifi-
cant increase in TGs and in TG-containing VLDL parti-
cles in association with colesevelam in GLOWS;
however, there was a significant increase in TG levels in
studies when colesevelam was added to sulfonylurea-
based therapy (17.7% vs placebo; P < 0.001) and insulin-
based therapy (21.5% vs placebo; P < 0.001), though not
metformin-based therapy (4.7% vs placebo; P = 0.22)
[76-79]. Adverse events associated with colesevelam
include gastrointestinal disturbances such as constipa-
tion, dyspepsia, and nausea [75].
The exact mechanism by which a bile acid sequestrant
may improve glycemic control in patients with type 2
diabetes is not fully understood, but may involve activa-
tion of the nuclear receptors farnesoid X receptor (FXR)
in the liver and intestine and TGR5 in the intestine
[72,81]. FXR is a bile acid-activated nuclear receptor
involved in the metabolism of cholesterol and glucose
[82,83]. Intestinal activation of FXR modulates multiple
downstream effects including those that affect glucose
and lipid metabolism through regulatory activity at
other sites including the liver X receptor, a potential
glucose sensor [70]. In vitro, TGR5 has been shown to
improve expression of the incretin hormone glucagon-
like peptide-1 (GLP-1), which improves insulin secre-
tion. Both colestimide and colesevelam have been
shown to increase GLP-1 in patients with type 2 dia-
betes and hypercholesterolemia [84,85]. Further studies
are needed to elucidate the mechanism(s) for bile acid
sequestrant-mediated regulation of glucose control.
Antihypertensive agents
Some antihypertensive agents are known to be lipid neu-
tral (angiotensin-converting enzyme inhibitors, calcium-
channel blockers, and angiotensin II receptor blockers)
or lipid friendly (a-blockers) [86]. In patients with type 2
diabetes and dyslipidemia, a lipid-neutral/friendly antihy-
pertensive would be expected to be associated with
greater clinical benefits than a lipid-hostile antihyperten-
sive such as a b-blocker or thiazide diuretic [87].
Dyslipidemia and renal function
In addition to being associated with an increased risk of
CVD, dyslipidemia is also associated with an increased
risk of renal dysfunction (increased serum creatinine
elevation and decline in glomerular filtration rate) in
patients with type 2 diabetes [88-90]. Chronic renal dys-
function can increase the risk of CVD. An analysis of
cardiac function in patients with type 2 diabetes and
end-stage renal disease showed that significantly more
patients with type 2 diabetes than without had impaired
cardiac function as measured by left ventricular
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Page 8 of 12hypertrophy (50% vs 38%, respectively; P =0 . 0 4 ) ,
ischemic heart disease (32% vs 18%; P = 0.003), and car-
diac failure (48% vs 24%; P< 0.0001) [91]. Therefore,
lowering lipid levels in patients with type 2 diabetes may
improve both cardiovascular risk and renal function.
Post-hoc analyses have shown that statin therapy is asso-
ciated with improved renal function in patients with dia-
betes and those with chronic renal insufficiency and
CVD [33,92]. In the MRC/BHF Heart Protection Study,
simvastatin improved renal function in patients with
type 2 diabetes [33]. However, it remains unclear
whether the beneficial renal effects of statins are a direct
result of reduced serum cholesterol levels or an as yet
undefined pleiotropic effect.
Conclusions
Type 2 diabetes is associated with a characteristic
atherogenic lipid pattern of elevated serum TGs, low
serum HDL-C levels, and a preponderance of small,
dense LDL particles. Disturbance of lipid metabolism
linked to insulin resistance may be the primary event in
the development of type 2 diabetes. The majority of
adults in the United States with type 2 diabetes do not
have optimal lipid profiles based on national guidelines.
In order to reduce the risk of CVD in patients with type
2 diabetes, physicians must initiate early and effective
lipid-lowering therapy. Although the first priority of
treatment is to lower LDL-C in patients with type 2 dia-
betes, the atherogenic pattern of dyslipidemia associated
with type 2 diabetes may require an advanced treatment
approach that ultimately aims for full normalization of
the lipid profile to decrease cardiovascular risk. Data
from combined prevalence studies suggest that poten-
tially all patients with type 2 diabetes may have an
abnormal lipid profile. Despite aggressive lipid-lowering
therapy, many patients with type 2 diabetes do not
achieve the recommended lipid levels to reduce their
CVD risk sufficiently. Adjuvant use of a bile acid
sequestrant such as colesevelam, having the dual effect
of improving both glycemic control and atherogenic
profile in patients with type 2 diabetes, may help
improve the overall management of type 2 diabetes in
some patients.
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